• home
  • articles
  • authors
  • Reviewers
  • About the Journal
  • About the Journal
  • About the Journal
  • About the Journal
  • e-Submission

Indexed/Covered by

J Vet Sci 2018; 19(1): 117-128  https://doi.org/10.4142/jvs.2018.19.1.117
Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial
Jonathan N. King1,*, Atsushi Hirakawa2, Junko Sonobe3, Hiroshi Otaki3, Nobuhiro Sakakibara3, Wolfgang Seewald1, Sophie Forster4
1Elanco Animal Health, Basel CH-4002, Switzerland
2Petclinic Halleluya Kasuya Hospital, Fukuoka 811-2304, Japan
3Elanco Japan K.K., Tokyo 107-0052, Japan
4Elanco Animal Health, Basingstoke RG24 9NL, United Kingdom
Correspondence to: Jonathan N. King
Tel: +41-61-685-6831; E-mail: jonathan.king@elanco.com
Received: September 1, 2016; Revised: March 1, 2017; Accepted: March 26, 2017; Published online: January 31, 2018.
Abstract
A fixed-dose combination tablet of benazepril and pimobendan (Fortekor Plus; Elanco Animal Health) was tested in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD) in a three-arm, masked, randomized, non-inferiority clinical trial in Japan. The test group (n = 34) received Fortekor Plus twice daily. Two control groups received registered formulations of benazepril (Fortekor; Elanco Animal Health) and pimobendan (Vetmedin; Boehringer Ingelheim Vetmedica) with administration of Vetmedin twice daily and Fortekor twice (Control I, n = 14) or once (Control II, n = 19) daily. Diuretics were used in 22 dogs (32.8%). Global clinical scores decreased significantly from baseline in all groups; there were no significant differences between groups, and non-inferiority of Fortekor Plus compared to Control I, Control II, and combined Control I + II groups was demonstrated. There were no significant differences between groups for relevant clinical chemistry and hematology variables or frequency of all adverse events. Frequency of emesis was significantly (p = 0.0042) lower in the Fortekor Plus (8.8%) group than in the Control I + II (39.4%) group. In conclusion, Fortekor Plus had non-inferior efficacy and was associated with significantly less emesis compared to Fortekor and Vetmedin in dogs with CHF caused by MMVD.
Keywords: benazepril, congestive heart failure, dogs, pimobendan


© 2018 The Korean Society of Veterinary Science.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.